Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Bortezomib and lenalidomide as first-line treatment for older patients with myeloma

Peter Barth • 13 Sep 2019
IMW 2019
Multiple Myeloma Bortezomib Cyclophosphamide Dexamethasone Lenalidomide

Peter Barth, MD, of Brown University, Providence, RI, discusses the benefit found in triplet induction therapy compared to that of various double induction therapies in elderly multiple myeloma patients in a retrospective study. This interview was recorded at the International Myeloma Workshop (IMW) 2019, in Boston, MA.

More from Peter Barth

0:58
Determining the prognostic significance of upfront radiation therapy in MM
Peter Barth • 14 Sep 2019

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals